Jaka jest cena za TMS Co., Ltd. (4891)

Cena za TMS Co., Ltd. (4891) wynosi $0.73072946

Jaka jest kapitalizacja rynkowa dla TMS Co., Ltd. (4891)

Kapitalizacja rynkowa dla TMS Co., Ltd. (4891) wynosi $33.30M

TMS Co., Ltd. (4891) Stopa Dywidendy

Established in 2005 and headquartered in Fuchu, Japan, TMS Co., Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceuticals, quasi-drugs, drug substances, medical devices, and various medical commodities. The company's pipeline includes TMS-007, an SMTP congener demonstrating both prothrombolytic and anti-inflammatory/antioxidative activities, which has advanced through Phase 2a clinical trials for the treatment of acute ischemic stroke. Additionally, TMS-008, another SMTP congener with anti-inflammatory/antioxidative properties, is undergoing nonclinical development for addressing inflammatory complications like acute kidney injury and cancer cachexia. A third product candidate, TMS-009, is currently in preclinical development. TMS Co., Ltd. collaborates with Hokkaido University and Kanazawa University to assess the potential of its drug candidates, has a joint research agreement with Teikyo University to identify renal function biomarkers, and maintains a strategic alliance with Ji Xing Pharmaceuticals Limited.

Rok	Stopa dywidendy	Zmień
Za mało danych dla podanych dat.

Rok

Stopa dywidendy

Zmień

Za mało danych dla podanych dat.

Firma	Stopa dywidendy	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Moderna, Inc. MRNA.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
CSL Limited CSL.AX	3.12%	AU
Lonza Group AG LONN.SW	0.00%	CH

Firma

Stopa dywidendy

Kraj

Vertex Pharmaceuticals Incorporated

VRTX.US

0.00%

Moderna, Inc.

MRNA.US

0.00%

Argenx SE

ARGX.US

0.00%

CSL Limited

CSL.AX

3.12%

Lonza Group AG

LONN.SW

0.00%

TMS Co., Ltd.

4891

Kategoria